Librax
Efficacy
IBS symptoms intensify when anxiety and stress disrupt the GBA balance 2-4
Physical symptoms of IBS are linked to neuro-transmitters, causing abnormal gut motility and sensory dysfunctions.2
Emotional states like anxiety and depression caused by stress increase the risk of hypersensitivity.5
The only IBS treatment that combines the antispasmodic effects of Clidinium Bromide and the anti-anxiety action of Chlordiazepoxide 6
Relief for the Stomach 1
LIBRAX® contains clidinium bromide which has a pronounced anti-spasmodic and anti-cholinergic effect on the gastrointestinal tract. 7
LIBRAX® containing clidinium bromide has antimuscarinic effects on the somatic components of IBS namely: 8,9
- Decreased smooth muscle motility 9
- Decreased GI activity 9
Relieving the symptoms of constipation, flatulence, diarrhoea and abdominal discomfort.9
Peace for the Mind 1
Benzodiazepine use should be expanded in GI disorders associated with anxiety.10
Benzodiazepines:
- Have muscle relaxant properties
- Contribute to patient well–being
- May facilitate the transition for pharmacotherapy to psychotherapy*
Treatment should be started with the lowest recommended dose.
- Reassess patient regularly. Re-evaluate continued treatment, especially if patient is symptom-free
- The maximum dose should not be exceeded
- The overall duration of treatment generally should not be more than 8 – 12 weeks, including a tapering off process†
*The tri-cyclic antidepressants, the SNRI’s and the SSRI’S are less suited for this role.
† Re- evaluate the patient carefully if this duration is to be exceeded.
IBS: irritable bowel syndrome; GBA: gut-brain axis; GI: gastro intestinal
Find balance with Librax®
Relief for the Stomach, Peace for the Mind 1
The 2-in-1 treatment for stress- related IBS
Reference :
- Librax. Professional Information. Viatris South Africa Pty Ltd. September 2023.
- Chen M, Ruan G, Chen L, Ying S, Li G, Xu F, et al. Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome. Front Endocrinol (Lausanne). 2022;13:817100.
- Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62(6):591-599.
- Arishi AM, Elmakki EE, Hakami OM, Alganmy OM, Maashi SM, Al-Khairat HK, et al. Irritable Bowel Syndrome: Prevalence and Risk Factors in Jazan Region, Saudi Arabia. Cureus. 2021;13(6):e15979.
- Pellissier S, Bonaz B. The Place of Stress and Emotions in the Irritable Bowel Syndrome. Vitam Horm. 2017;103:327- 354.
- IMS Pricing Data – January 2025.
- PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. PubChem Compound Summary for CID 19004, Clidinium Bromide; [cited 2025 Mar. 13]. Available from URL: https://pubchem.ncbi.nlm.nih.gov/compound/Clidinium-Bromide
- DrugBank. Cidinium. [Online] 2025 MAR 11. [Cited 2025 Mar 13]; Available from URL: https://go.drugbank.com/drugs/DB00771
- Singh A. Antimuscarinics. Osmosis. [Online] 2025 Mar 04. [Cited 2025 Apr10]; Available form URL: https://www.osmosis.org/answers/ antimuscarinics
- Balon R, Sonino N, Rafanelli C. Benzodiazepines’ Role in Managing Gastrointestinal Disorders. Psychoter Psychosom 2021;90:81-84. DOI: 10.1159/000510686.